Regulatory identification of BPA as an endocrine disruptor: Context and methodology

C. Beausoleil, C. Emond, J. P. Cravedi, J. P. Antignac, M. Applanat, B. M.R. Appenzeller, R. Beaudouin, L. P. Belzunces, M. C. Canivenc-Lavier, N. Chevalier, C. Chevrier, E. Elefant, F. Eustache, R. Habert, M. Kolf-Clauw, B. Le Magueresse-Battistoni, S. Mhaouty-Kodja, C. Minier, L. Multigner, H. SchroederP. Thonneau, C. Viguié, F. Pouzaud, J. N. Ormsby, C. Rousselle, L. Verines-Jouin, E. Pasquier*, C. Michel

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

85 Citations (Scopus)


BPA is one of the most investigated substances for its endocrine disruptor (ED) properties and it is at the same time in the center of many ED-related controversies. The analysis on how BPA fits to the regulatory identification as an ED is a challenge in terms of methodology. It is also a great opportunity to test the regulatory framework with a uniquely data-rich substance and learn valuable lessons for future cases. From this extensive database, it was considered important to engage in a detailed analysis so as to provide specific and strong evidences of ED while reflecting accurately the complexity of the response as well the multiplicity of adverse effects. An appropriate delineation of the scope of the analysis was therefore critical. Four effects namely, alterations of estrous cyclicity, mammary gland development, brain development and memory function, and metabolism, were considered to provide solid evidence of ED-mediated effects of BPA.

Original languageEnglish
Pages (from-to)4-9
Number of pages6
JournalMolecular and Cellular Endocrinology
Publication statusPublished - 5 Nov 2018


  • Bisphenol A
  • ED
  • Endocrine disruption
  • REACh
  • SVHC
  • Substance of very high concern


Dive into the research topics of 'Regulatory identification of BPA as an endocrine disruptor: Context and methodology'. Together they form a unique fingerprint.

Cite this